健康元：后续，公司将持续与审评中心保持密切沟通

Group 1 - The core viewpoint of the article is that the上市审评 (listing review) of 玛帕西沙韦 (TG-1000) capsules is progressing normally, with the company actively addressing regulatory requirements [2] - The company has completed the organization and submission of relevant materials in response to the regulatory body's request for supplementary verification of the label and related documents [2] - The company will maintain close communication with the review center and actively cooperate with all review work to expedite the product review process [2]